Update on the issues of HIV vaccine development

Annals of Medicine

Volumn 28, Issue 1, 1996, Pages 39-41

  Haynes, Barton F ^a   Putman, Shannon B ^a   Weinberg, Jason B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Animal models; Immunization; Pathogenesis

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; CLINICAL TRIAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY; THAILAND; UNITED STATES; VACCINATION; VIRUS IMMUNITY;

EID: 0030041957     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899608999072     Document Type: Short Survey

References (23)

1. WHO Global Programme on AIDS. Current and future dimensions of the HIV/AIDS pandemic: a capsule summary, January 1992. Brochure RES/SF1/92.1: 1-17.
2. Berzofsky JA. Development of artificial vaccines against HIV using defined epitopes. FASEB J 1991; 5: 2412-8.
3. Haynes BF, Pantaleo G, Fauci AS. Towards an understanding of the correlates of protective immunity to HIV infection. Science (in press).
4. Wolinsky SM, Wike CM, Korber BT, et al. Selective transmission of HIV type 1 variants from mothers to infants. Science 1992; 255: 1134-7.
5. Pauza CD, Malkovsky M, Salvato MS. SIV transmission across the mucosal barrier. AIDS Res Hum Retroviruses 1994; 10 (Suppl 1): S7-10.
6. Matthews TJ. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res Hum Retroviruses 1994; 10: 633-6.
7. Wain-Hobson S. Is antigenic variation of HIV important for AIDS and what might be expected in the future? In: Morse SSB, ed. The Evolutionary Biology of Retroviruses. New York: Raven, 1994: 185-209.
8. Cheynier R, Henrichwark S, Hadida F, et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994; 78: 373-87.
9. Sala M, Zambruno G, Vartanian JP, Marconi A, Bertazzoni U, Wain-Hobson S. Spatial discontinuities in human immunodeficiency virus type 1 quasispecies derived from epidermal Langerhan's cells of a patient with AIDS and evidence for double infection. J Virol 1994; 68: 280-3.
10. Haynes BF. Scientific and social issues of human immunodeficiency virus vaccine development. Science 1993; 260: 1279-86.
11. Robinson WE Jr, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 1990; 64: 5301-5.
12. Kohler H, Goudsmit J, Nara P. Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. J Acquir Immune Defic Syndr 1992; 5: 1158-68.
13. Arthur LO, Bess JW Jr, Sowder RC II, et al. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 1992; 258: 1935-8.
14. Cianclolo GJ, Matthews TJ, Bolognesi DP, Snyderman R. Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol 1980; 124: 2900-5.
15. Ruegg CL, Strand M. A synthetic peptide with sequence identity to the transmembrane protein gp41 of HIV-1 inhibits distinct lymphocyte activation pathways dependent on protein kinase C and intracellular calcium influx. Cell Immunol 1991; 137: 1-13.
16. Haynes BF, Arthur LO, Frost P, et al. Conversion of an immunogenic human immunodeficiency (HIV) envelope synthetic peptide to a toleragen in chimpanzees by the fusogenic domain of HIV gp41 envelope protein. J Exp Med 1993; 177: 717-27.
17. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
18. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Makowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6.
19. Mosier DE, Gulizia RJ, MacIsaac PD, Torbett BE, Levy JA. Rapid loss of CD4+T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 1989; 260: 689-92.
20. Schuitemaker HL, Meyaard L, Kootstra NA, et al. Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J Infect Dis 1993; 168: 1140-7.
21. Ennen J, Findeklee H, Dittmar MT, Norley S, Ernst M, Kurth R. CD8+ lymphocytes of African green monkeys secrete an immunodeficiency virus-suppressing lymphokine. Proc Natl Acad Sci USA 1994; 91: 7207-11.
22. Haynes BF. Vaccine strategies for HIV infection. In: Golematis BC, Syrigos KN, eds. AIDS and Malignancies: Current Concepts and Prospectives. Chichester, UK: John Wiley & Sons Ltd (in press).
23. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270: 988-91.